Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant
survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the …

The treatment of metastatic castrate-resistant prostate cancer has been historically
challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy …

Simple Summary Therapeutic options for the treatment of men with metastatic castration-
resistant prostate cancer are limited. Docetaxel—a taxane-based chemotherapeutic agent …

Drug development for castration resistant prostate cancer (CRPC) is challenging, since this
cancer is still associated with high mortality and limited therapeutic options. In 2004 …

Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in
prostate cancer. Recent clinical data show that docetaxel combined with androgen …

Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-
resistant prostate cancer (CRPC). However, most patients eventually develop resistance to …

Recent studies have shown that docetaxel-based chemotherapy confers a survival benefit in
patients with castration-resistant prostate cancer (PC). Also epidermal growth factor receptor …

The androgen receptor (AR) plays an essential role in prostate cancer, and suppression of
its signaling with androgen deprivation therapy (ADT) has been the mainstay of treatment for …

The mechanisms of docetaxel resistance in PC (prostate cancer) are unclear because of the
lack of suitable experimental models, and no effective treatment exists for docetaxel …

Docetaxel in combination with prednisone is the standard of care in men with symptomatic
castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with …